SAMLIP Reports 78.9% Drop in Third-Quarter Operating Profit, but... “Trend of Improvement Each Quarter”
Revenue of 823.4 billion won, down 4.6% year-over-year… Operating profit of 1.9 billion
"Fourth-Quarter Earnings Expected to Improve Thanks to Overseas Growth and Ho-Bbang Sales"
[Edaily Reporter kim mi-kyung ] SAMLIP announced on the 16th that its consolidated operating profit for the third quarter of this year was 1.9 billion won. This represents a 78.9% decrease compared to the same period last year (approximately 9.1 billion won).
Revenue for the same period was 823.4 billion won, down 4.6% from the same period last year (863.1 billion won). According to SPC SAMLIP(005610), revenue declined due to the restructuring of the business to prioritize profitability, while operating profit fell year-over-year due to cost pressures resulting from increased safety investments and rising raw material prices.
However, quarterly performance is showing a trend of improvement. While the company posted a loss in the first quarter of this year, it returned to profitability in the second quarter, and third-quarter operating profit increased compared to the previous quarter. SAMLIP’s operating profit for the second quarter of this year was 110 million won.
A SAMLIP official stated, “Operating profit is steadily improving through the restructuring of our business model to prioritize profitability, and positive changes are emerging, such as global business growing by more than 50 percent,” adding, “We expect performance to improve further in the fourth quarter due to expanded overseas exports and increased sales of flagship products such as Ho-bbang.”
LG Energy Solution delivered encouragement gifts to the children of its employees ahead of the 2027 College Scholastic Ability Test.
LG Energy Solution’s 2027 College Scholastic Ability Test gift p…
SAMLIP announced on the 16th that its consolidated operating profit for the third quarter of this year was 1.9 billion won. This represents a 78.9% decrease compared to the same period last year (appr…
DaewonPharmaceutical(003220)Daewon Pharmaceutical is embarking on the development of a pediatric antipyretic based on “Felubi,” Korea’s 12th domestically developed new drug. This comes approximately 2…